Hollak CE - Search Results

1

Ultrastructural analysis of dermal fibroblasts in mucopolysaccharidosis type I: Effects of enzyme replacement therapy and hematopoietic cell transplantation.

Cox-Brinkman J, van den Bergh Weerman MA, Wijburg FA, Aerts JM, Florquin S, van der Lee JH, Hollak CE. Cox-Brinkman J, et al. Among authors: hollak ce. Ultrastruct Pathol. 2010 May;34(3):126-32. doi: 10.3109/01913121003648485. Ultrastruct Pathol. 2010. PMID: 20455661

2

[Gaucher's disease; current developments in the treatment of lysosomal metabolic disease].

Hollak CE, Aerts JM, Goudsmit R. Hollak CE, et al. Ned Tijdschr Geneeskd. 1991 Nov 16;135(46):2162-4. Ned Tijdschr Geneeskd. 1991. PMID: 1956441 Review. Dutch. No abstract available.

3

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.

Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH. Hollak CE, et al. Lancet. 1995 Jun 10;345(8963):1474-8. doi: 10.1016/s0140-6736(95)91037-9. Lancet. 1995. PMID: 7769902 Clinical Trial.

4

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Hollak CE, van Weely S, van Oers MH, Aerts JM. Hollak CE, et al. J Clin Invest. 1994 Mar;93(3):1288-92. doi: 10.1172/JCI117084. J Clin Invest. 1994. PMID: 8132768 Free PMC article.

5

Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease.

Aerts JM, Van Weely S, Boot R, Hollak CE, Tager JM. Aerts JM, et al. Among authors: hollak ce. J Inherit Metab Dis. 1993;16(2):288-91. doi: 10.1007/BF00710267. J Inherit Metab Dis. 1993. PMID: 8411983 Review. No abstract available.

6

[The treatment of Gaucher's disease in The Netherlands using enzyme substitution therapy].

Hollak CE, van Oers MH, Maaswinkel P, Aerts JM, Goudsmit R. Hollak CE, et al. Ned Tijdschr Geneeskd. 1996 May 11;140(19):1011-3. Ned Tijdschr Geneeskd. 1996. PMID: 8684492 Review. Dutch. No abstract available.

7

The effect of enzyme therapy in a patient with Gaucher disease type III.

Bosman DK, Hollak CE, Aerts JM, Bakker HD. Bosman DK, et al. Among authors: hollak ce. J Inherit Metab Dis. 1996;19(5):703-4. doi: 10.1007/BF01799852. J Inherit Metab Dis. 1996. PMID: 8892032 No abstract available.

8

Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy.

Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH. Hollak CE, et al. Br J Haematol. 1997 Mar;96(3):470-6. doi: 10.1046/j.1365-2141.1997.d01-2076.x. Br J Haematol. 1997. PMID: 9054650 Free article.

9

Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease.

Hollak CE, Evers L, Aerts JM, van Oers MH. Hollak CE, et al. Blood Cells Mol Dis. 1997 Aug;23(2):201-12. doi: 10.1006/bcmd.1997.0137. Blood Cells Mol Dis. 1997. PMID: 9236158

10

Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease.

Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, van Oers MH. Hollak CE, et al. Am J Med. 1997 Sep;103(3):185-91. doi: 10.1016/s0002-9343(97)00134-4. Am J Med. 1997. PMID: 9316550

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

330 results

Search Page

Filters